期刊文献+

临床药师参与1例肝肾联合移植术后他克莫司的用药监护

Pharmaceutical care for a patient treated with tacrolimus after liver and renal transplantation
下载PDF
导出
摘要 临床药师以1例肝肾联合移植术后移植受者的他克莫司血药浓度波动为切入点,通过基因检测技术、治疗药物监测等精准化药学手段,为患者提供个体化的药物服务,制订个体化的他克莫司治疗方案,指导临床合理用药。在患者的临床治疗过程中,临床药师对肝肾联合移植受者开展药学服务实践并发挥作用,建立肝肾联合移植受者精准化药学服务的模式,保证了患者用药的安全性和有效性。 With the assistance of advanced and precise pharmaceutical means,such as gene detection and therapeutic drug monitoring,clinical pharmacists measured the fluctuations of tacrolimus blood concentrations in one transplant recipient after combined liver-kidney transplantation as the breakthrough point,to provide individualized drug services for patients,to develop individualized tacrolimus treatment plan,and to guide the clinical rational drug use.In the clinical treatment,pharmaceutical care was provided and it played a role in the recipient with combined liver-kidney transplant.A precise pharmaceutical care model for combined liver-kidney transplantation recipient has been established,to ensure the safety and efficacy of the medication.
作者 王菁菁 邹吉利 WANG Jing-jing;ZOU Ji-li(Wuhan Third Hospital,Wuhan 430060)
机构地区 武汉市第三医院
出处 《中南药学》 CAS 2020年第5期863-866,共4页 Central South Pharmacy
关键词 肝肾联合移植 他克莫司 血药浓度 基因多态性 药学监护 combined liver-kidney tranplantation tacrolimus blood drug concentration gene polymorphism pharmaceutical care
  • 相关文献

参考文献8

二级参考文献63

  • 1Hommann M,Schotte U.Cerebral toxoplasmosis after combined liver pancreas-kidney and liver-pancreas transplantation[J].Transplant Proc,2002,34:2294-2295.
  • 2Starzl CE,Willis C,Taylor PJ,et al.Population pharmacokinetics of tacrolimus in adult kidney transplant recipients[J].Clin Pharmacol Ther,2002,72:660-669.
  • 3Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3 A5 expression. Nat Genet, 2001,27 (4) : 383-391.
  • 4Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs, 2005,65 (6) :827-858.
  • 5Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol, 2002,62 ( 1 ) : 162-172.
  • 6Hoffmeyer S, Burk O, yon Richter, et al. Functional polymorphisms of the human multidrug- resistance gene : multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 2000,97 ( 7 ) : 3473- 3478.
  • 7Emoto C, Murayarna N, Wakiya S, et al. Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reeonstitutian systems. Drug Metab Lett, 2009,3 (4) :207-211.
  • 8Li D, Zhang GL, Lou YQ, et al. Genetie polymorphisms in MDR1 and CYP3A5 and MDRI haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther, 2007,32( 1 ) :89-95.
  • 9Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharrnaeokineties of taerolimus. Clin Pharmacokinet, 1995,29 ( 6 ) : 404-430.
  • 10Wallemaeq PE, Verbeeek RK. Comparative clinical pharmaeokineties of tacrolimus in paediatric and adult patients. Clin Pharmaeokinet, 2001,40(4) :283-295.

共引文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部